Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Antifibrosing Activity of POTABA in Agnogenic and Post-Polycythemic Myeloid Metaplasia

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Treatment Closed no age specified PVSG-7

Objectives

I.  Determine by bone marrow section examination, whether POTABA has any 
antifibrosing action in patients with agnogenic myeloid metaplasia (AMM) and 
post-polycythemic myeloid metaplasia (PPMM).

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Asymptomatic patients with AMM and 
PPMM with increasing spleen size (increasing splenomegaly for PPMM), absence 
of elevated red cell volume, development of leukoerythroblastic blood reaction 
plus appearance of fibrosis in AMM, tear drop poikilocytes and increased both 
marrow reticulin and/or fibrosis in PPMM.  AMM patients must not have had 
prior chemotherapy.

Expected Enrollment

Protocol closed 11/79.

Outline

Nonrandomized study.
Single-agent Vitamin Therapy.  Potassium P-aminobenzoate, POTABA, no NSC 
number.

Trial Contact Information

Trial Lead Organizations

Polycythemia Vera Study Group

Louis R. Wasserman, MD, Protocol chair
Ph: 212-289-3466

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.